News

Understanding Dividend Rates for Manulife's Preferred Shares

Understanding Dividend Rates for Manulife's Preferred Shares

Introduction to Manulife Financial Corporation's Dividend Announcement

Manulife Financial Corporation constantly strives to enhance financial services for its clients. As part of this commitment, the company has announced its latest dividend rates for the Non-cumulative Rate Reset Class 1 Shares Series 19 and Non-cumulative Floating Rate Class 1 Shares Series 20. Understanding these rates can help investors make informed decisions about their investments.

Details of the Series 19 Preferred Shares

Dividend Payments and Rates

For the Series 19 Preferred Shares, which continue to remain after the specified date, shareholders will benefit from a fixed rate non-cumulative preferential cash dividend. This will be paid quarterly as declared by Manulife's Board of Directors. Starting from a specified future date, the dividend rate for the five-year term will be set at an impressive 5.16900% per annum. This translates to a payment of approximately C$0.323063 per share for each quarter.

Yield Calculation

The dividend is determined based on the yield of the five-year Government of Canada bond, which is adjusted with an additional 2.30% margin. This calculation ensures that it provides a competitive return that reflects current market conditions.

About the Series 20 Preferred Shares

Conversion Rights and Floating Rate Dividends

Investors looking to convert their Series 19 shares into Series 20 shares will find favorable terms. Upon conversion, the holders of Series 20 Preferred Shares will receive floating rate non-cumulative preferential cash dividends, calculated on the actual number of days in each quarterly period relative to a year. Initially, the dividend rate for the new Series 20 shares during the first three-month period will be approximately 1.29430%, amounting to about C$0.323575 per share. This yield is based on the current three-month Government of Canada Treasury bill yield plus the same 2.30% additional margin.

Conversion Instructions and Assistance

Holders of the Series 19 shares who wish to exercise their right of conversion are encouraged to engage their brokers or designated nominees to facilitate this process. The deadline for conversions is set for a specified time, ensuring that investors have a clear timeline to act. For any inquiries regarding conversions, Manulife's Registrar and Transfer Agent is available for assistance.

Listing Information for Series 20 Shares

Stock Exchange Approvals

Manulife is actively working to meet the listing requirements for the Series 20 Preferred Shares on the Toronto Stock Exchange (TSX). This process is crucial for ensuring that the shares can be actively traded, further enhancing liquidity for investors. Once approved, the Series 20 shares will be traded under the ticker symbol 'MFC.PR.S'.

Investments Not Registered in the U.S.

It's important to note that neither the Series 19 nor the Series 20 Preferred Shares have been registered under the United States Securities Act or any applicable state laws. This means that the shares can’t be sold or delivered directly within the United States, unless under specific exemptions. Investors should be aware of these regulations when considering their investment options.

About Manulife Financial Corporation

Manulife Financial Corporation stands as a leading international provider of financial services. With its headquarters situated in Canada, the company provides a broad range of financial advice and insurance solutions. Operating under the Manulife brand in Canada, Asia, and Europe, and as John Hancock in the United States, it emphasizes customer service and satisfaction. With a strong workforce exceeding 38,000 employees and a network of over 98,000 agents, Manulife notably serves more than 35 million customers worldwide. Investors can find Manulife's stock traded as 'MFC' across major exchanges including those in Canada and the United States, with operations also in Hong Kong.

Frequently Asked Questions

What are the new dividend rates for Manulife's shares?

The new dividend rate for the Series 19 Preferred Shares is 5.16900% per annum, while the initial rate for the Series 20 Preferred Shares is set at 1.29430% for the first three-month period.

How frequently will the dividends be paid?

The dividends for both Series 19 and Series 20 Preferred Shares are paid on a quarterly basis, as declared by the company’s Board of Directors.

What steps should I take if I want to convert my Series 19 shares?

To convert your Series 19 shares, you should contact your broker or nominee before the conversion deadline.

Are these shares available for purchase in the U.S.?

No, the Series 19 and Series 20 Preferred Shares have not been registered in the U.S. and cannot be sold or offered directly there.

What is the significance of the additional 2.30% margin?

The 2.30% margin is added to the Government of Canada bond yield or Treasury bill yield to ensure that the returns on the preferred shares provide a competitive edge in the market.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

One Stop Swap eyes school fundraising for growth

Updated Category News Views 172

Transforming Fundraising with a Marketplace Twist Sometimes the real treasures are not tucked in textbooks but found in cluttered closets and basements. Enter One Stop Swap with a big idea—they're cooking up a fundraising strategy for schools that could shake things up by helping families sell their unused stuff. It's got that grassroots vibe with the potential to carve...

Continue Reading
Lectric Rolls Out Limited-Edition XP4 Ebike Upgrades

Updated Category News Views 51

Pedaling into a New Era of eBikes When the top contender in the American eBike world rolls out something new, you'd better believe it's worth a look. Lectric eBikes has just unwrapped three limited-edition versions of their beloved XP4, revealing a fresh take on a ride already admired by thousands. Let's dig into this new release. What's New with the XP4 This ain't just a...

Continue Reading
Florida Cancer Institute Expands: New Oncologist Joins Team

Updated Category News Views 0

News in the medical world isn't just rattling desks today; it's a purposeful signal for cancer care's transformation. Florida Cancer Specialists & Research Institute (FCS) has beefed up its team, embracing Carlos Barbur, DO, an oncologist who's not just skilled but steeped in disciplines crucial for the health of many. Think of this as another puzzle piece fitting snugly...

Continue Reading
MetaOptics Expands U.S. Reach with ADR Programme

Updated Category News Views 107

A Bold Move into the U.S. Market MetaOptics Ltd, the semiconductor optics dynamo out of Singapore, is kicking up some investment dust with their American Depositary Receipts (ADR) Programme aimed squarely at expanding its U.S. footprint. And let me tell you, in the game of international market expansion, that's no rookie maneuver. Why ADR? Why Now? So, why is MetaOptics...

Continue Reading
Target Hospitality Readies for Q3 2026 Earnings Reveal

Updated Category News Views 42

The Thrill of Earnings Season Every trader worth their salt gets a tingle down the spine come earnings season. There's nothing quite like it—the build-up, the anticipation, the potential payouts. This time, we're zeroing in on Target Hospitality, bearing the ticker NASDAQ: TH. Come November 9, 2026, they're set to unveil what the past quarter had up its sleeve, and like...

Continue Reading
Endeavor & GoPath's Game-Changing Cancer Test Launch

Updated Category News Views 0

Breaking Ground in Prostate Cancer Testing Just when you thought the medical field couldn't shake things up further, Endeavor Health and GoPath Diagnostics swoop in with a new genetic test for prostate cancer. This ain't just any run-of-the-mill test—it's the first of its kind to hit the clinical scene. The focus here is on sorting out which men with prostate cancer are...

Continue Reading
Nanchang Expo Showcases Future of Aviation and Space

Updated Category News Views 242

Aviation Dreams Take Off in Nanchang Not every day you see an expo spanning 30,000 square meters focused on aviation, especially where East meets innovation—Nanchang, the beating heart of Jiangxi Province, China, is where it's all happening this time around. October 31, 2026, saw the city launching not rockets but the 2026 Nanchang Aviation Industry Expo, and folks,...

Continue Reading
TAL's Festive Drinkware Hits Walmart for the Holidays

Updated Category News Views 0

Walmart's Shelves Get Festive with TAL's New Lineup Alright, so we've got TAL rolling out a limited-edition Holiday Coffee Collection exclusively at Walmart stores. You might wonder why a hydration brand is grabbing headlines right now, but listen up—this stuff just hit on November 2 and it's got the sparkle everyone's eyeing this season. What's Inside this Festive...

Continue Reading
Atrium's Heart Therapies: ATR 1072's Promising Data

Updated Category News Views 40

Atrium Therapeutics Strikes a Chord with New Data Tuning into the heartbeats of breakthrough developments, Atrium Therapeutics dropped some fresh, nonclinical insights about their latest contender, ATR 1072. This wasn't just any ordinary announcement; it's like when the market hears whispers of a Fed rate adjustment. The venue? The American Heart Association's 2026...

Continue Reading
Baystate Health Expands: A New Chapter with Mercy

Updated Category News Views 157

Baystate Health Moves Forward with Strategic Integration Well, here's a tale that's as much about legacy as it is about progress. Baystate Health has brought Baystate Mercy Hospital into its fold, blending history with future prospects. This integration, folks, isn't just a merger—it's a downright overhaul of how healthcare operates in Western Massachusetts. We’re...

Continue Reading

Top 5 Most Recently Viewed Articles

Twin Disc Offers Insight at Upcoming Growth Conference

Updated Category News Views 101

Twin Disc's Upcoming Presentation at a Key Conference Twin Disc, Inc. (NASDAQ: TWIN) is gearing up to make a notable appearance at the upcoming Noble Capital Markets Emerging Growth Equity Conference. The event will take place in Boca Raton and is set for a pivotal moment when Chief Financial Officer Jeff Knutson takes the stage to share insights into the company's future...

Continue Reading
Keymed Biosciences Achieves Milestone with Stapokibart Approval

Updated Category News Views 85

Keymed Biosciences Inc. Receives Approval for Stapokibart Keymed Biosciences Inc. (HKEX: 02162) has made impressive advancements in dermatological treatments with the recent marketing approval of Stapokibart. This innovative therapy targets moderate-to-severe atopic dermatitis in adults and has received endorsement from the National Medical Products Administration, the...

Continue Reading
Harnessing AI for Next-Level Value Creation in Tech Firms

Updated Category News Views 215

Harnessing AI for Next-Level Value Creation in Tech Firms In today's fast-paced technological landscape, the integration of artificial intelligence (AI) is reshaping the operational dynamics of companies. Innovators are exploring the potential of AI to redefine services, optimize processes, and create new avenues for revenue generation. In a notable address, an industry...

Continue Reading
CoinShares Reveals Successful Exercise of Share Options

Updated Category News Views 229

CoinShares Executes Employee Share Options with Success CoinShares International Limited (Nasdaq Stockholm Market: CS; US OTCQX: CNSRF) has made a significant announcement regarding its Employee Incentive Plan. Recently, the firm revealed that it has successfully exercised a total of 25,000 options from its Employee Incentive Plan - November 2020 Tranche. This is an...

Continue Reading
EverQuote's Impressive Q3 2025 Performance Highlights

Updated Category News Views 157

EverQuote Reports Strong Growth in Q3 2025 EverQuote, Inc. (Nasdaq: EVER), a prominent player in the online insurance marketplace, has revealed impressive financial results for the third quarter of 2025, showing significant growth across several critical metrics. Revenue surged by 20% year-over-year, reaching $173.9 million, reflecting the company's effective strategies...

Continue Reading